| pubmed-article:9142008 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9142008 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9142008 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:9142008 | lifeskim:mentions | umls-concept:C0033262 | lld:lifeskim |
| pubmed-article:9142008 | lifeskim:mentions | umls-concept:C0002335 | lld:lifeskim |
| pubmed-article:9142008 | lifeskim:mentions | umls-concept:C0021775 | lld:lifeskim |
| pubmed-article:9142008 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:9142008 | lifeskim:mentions | umls-concept:C0599724 | lld:lifeskim |
| pubmed-article:9142008 | lifeskim:mentions | umls-concept:C0671096 | lld:lifeskim |
| pubmed-article:9142008 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:9142008 | pubmed:dateCreated | 1997-6-5 | lld:pubmed |
| pubmed-article:9142008 | pubmed:abstractText | Intermittent claudication due to peripheral arterial occlusive disease (PAOD) is a common cause of pain and disability in the middle-aged. Clinical trials of the potent vasodilator prostaglandin E1 have been disappointing. This is the first report of a controlled clinical trial of AS-0:3, a novel prodrug of prostaglandin E1 incorporated into lipid microspheres that has been developed to improve delivery of the active compound to blood vessel walls. | lld:pubmed |
| pubmed-article:9142008 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9142008 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9142008 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9142008 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9142008 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9142008 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9142008 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9142008 | pubmed:month | May | lld:pubmed |
| pubmed-article:9142008 | pubmed:issn | 0009-7322 | lld:pubmed |
| pubmed-article:9142008 | pubmed:author | pubmed-author:MizushimaYY | lld:pubmed |
| pubmed-article:9142008 | pubmed:author | pubmed-author:DormandyJ AJA | lld:pubmed |
| pubmed-article:9142008 | pubmed:author | pubmed-author:RuckleyC VCV | lld:pubmed |
| pubmed-article:9142008 | pubmed:author | pubmed-author:BellP RPR | lld:pubmed |
| pubmed-article:9142008 | pubmed:author | pubmed-author:WolfeJ HJH | lld:pubmed |
| pubmed-article:9142008 | pubmed:author | pubmed-author:KesterR CRC | lld:pubmed |
| pubmed-article:9142008 | pubmed:author | pubmed-author:ScurrJ HJH | lld:pubmed |
| pubmed-article:9142008 | pubmed:author | pubmed-author:BelchJ JJJ | lld:pubmed |
| pubmed-article:9142008 | pubmed:author | pubmed-author:CreissenDD | lld:pubmed |
| pubmed-article:9142008 | pubmed:author | pubmed-author:McCollumR DRD | lld:pubmed |
| pubmed-article:9142008 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9142008 | pubmed:day | 6 | lld:pubmed |
| pubmed-article:9142008 | pubmed:volume | 95 | lld:pubmed |
| pubmed-article:9142008 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9142008 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9142008 | pubmed:pagination | 2298-302 | lld:pubmed |
| pubmed-article:9142008 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9142008 | pubmed:meshHeading | pubmed-meshheading:9142008-... | lld:pubmed |
| pubmed-article:9142008 | pubmed:meshHeading | pubmed-meshheading:9142008-... | lld:pubmed |
| pubmed-article:9142008 | pubmed:meshHeading | pubmed-meshheading:9142008-... | lld:pubmed |
| pubmed-article:9142008 | pubmed:meshHeading | pubmed-meshheading:9142008-... | lld:pubmed |
| pubmed-article:9142008 | pubmed:meshHeading | pubmed-meshheading:9142008-... | lld:pubmed |
| pubmed-article:9142008 | pubmed:meshHeading | pubmed-meshheading:9142008-... | lld:pubmed |
| pubmed-article:9142008 | pubmed:meshHeading | pubmed-meshheading:9142008-... | lld:pubmed |
| pubmed-article:9142008 | pubmed:meshHeading | pubmed-meshheading:9142008-... | lld:pubmed |
| pubmed-article:9142008 | pubmed:meshHeading | pubmed-meshheading:9142008-... | lld:pubmed |
| pubmed-article:9142008 | pubmed:meshHeading | pubmed-meshheading:9142008-... | lld:pubmed |
| pubmed-article:9142008 | pubmed:meshHeading | pubmed-meshheading:9142008-... | lld:pubmed |
| pubmed-article:9142008 | pubmed:meshHeading | pubmed-meshheading:9142008-... | lld:pubmed |
| pubmed-article:9142008 | pubmed:meshHeading | pubmed-meshheading:9142008-... | lld:pubmed |
| pubmed-article:9142008 | pubmed:meshHeading | pubmed-meshheading:9142008-... | lld:pubmed |
| pubmed-article:9142008 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9142008 | pubmed:articleTitle | Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. | lld:pubmed |
| pubmed-article:9142008 | pubmed:affiliation | Ninewells Hospital and Medical School, Dundee, UK. | lld:pubmed |
| pubmed-article:9142008 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9142008 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9142008 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:9142008 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9142008 | pubmed:publicationType | Multicenter Study | lld:pubmed |
